Doctor of Osteopathy Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Martin Kerzer

Family Medicine Warwick, RI Doctor of Osteopathy

NPI 1962495416 CMS profile 179260

857 Post Rd, Warwick, RI 02888

Open in the dashboard

General payments

$7,354

471 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Martin Kerzer of Warwick, RI is reported in the CMS Open Payments database as having received $7,354 across 471 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $13 1
2022 General $400 17
2021 General $2,543 157
2020 General $1,702 109
2019 General $2,696 187

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Martin Kerzer
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Martin Kerzer were reported at $0. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Martin Kerzer Family Medicine median Middle half National median
2019 $2,696 $150 $41–$543 $163
2020 $1,702 $120 $32–$415 $114
2021 $2,543 $137 $35–$551 $132
2022 $400 $137 $37–$512 $149
2023 $0 $149 $42–$545 $160
2024 $13 $156 $44–$560 $164
2025 $0 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AstraZeneca Pharmaceuticals LP $1,206 77 payments
  2. GlaxoSmithKline, LLC. $1,034 63 payments
  3. Novo Nordisk Inc $799 49 payments
  4. Janssen Pharmaceuticals, Inc $623 38 payments
  5. Pfizer Inc. $561 66 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $517 26 payments
  7. Sanofi-Aventis U.S. LLC $494 24 payments
  8. AbbVie, Inc. $356 26 payments
  9. Lilly USA, LLC $265 17 payments
  10. E.R. Squibb & Sons, L.L.C. $187 6 payments
  11. Other $1,313 79 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $7,299 465 payments
  2. Education $56 6 payments
Products named General payments · program years 2019–2024
  1. FARXIGA $714 45 payments
  2. TRELEGY ELLIPTA $691 41 payments
  3. XARELTO $623 38 payments
  4. Ozempic $533 33 payments
  5. SPIRIVA RESPIMAT $367 19 payments
  6. RYBELSUS $365 24 payments
  7. SYMBICORT $348 19 payments
  8. ELIQUIS $320 24 payments
  9. CREON $285 22 payments
  10. SOLIQUA 100/33 $270 13 payments
  11. Other $5,374 380 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

471 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Rhode Island

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record